Alternatives to dolutegravir/lamivudine
1 same-class SPL records vs dolutegravir/lamivudine - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Dovato
About dolutegravir/lamivudine
Dovato is a complete HIV-1 treatment that combines two medicines into one tablet. It is used for adults and adolescents who weigh at least 55 pounds.
Used for: Dovato is used to treat HIV-1 infection in adults and adolescents (12 years and older, weighing at least 55 pounds). It can be used if you have never taken HIV-1 medicines before. It can also be used to replace your current HIV-1 medicines if your virus is under control (HIV-1 RNA less than 50 copies/mL) and you have not had treatment failure or resistance to the medicines in Dovato.
1 Integrase Inhibitor / NRTI Combination peers (wide set)
Compare dolutegravir/lamivudine vs bictegravir/emtricitabine/tenofovir side-by-side →
dolutegravir/lamivudine vs bictegravir/emtricitabine/tenofovir · FAERS reaction fields
FAERS top-reaction field "Pain" shows the widest count spread between dolutegravir/lamivudine and bictegravir/emtricitabine/tenofovir in this extract (1,425-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | dolutegravir/lamivudine | bictegravir/emtricitabine/tenofovir |
|---|---|---|
| Pain | 1,425 | - |
| Anxiety | 1,051 | - |
| Emotional Distress | 1,048 | - |
| Anhedonia | 942 | - |
| Chronic Kidney Disease | 701 | - |
| Fatigue | 628 | - |
| Exposure During Pregnancy | 606 | - |
| Headache | 566 | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
dolutegravir/lamivudine peer mix vs class inventory
Peer mix
0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for Integrase Inhibitor / NRTI Combination: 2 drugs.
Frequently Asked Questions
What same-class SPL records sit beside dolutegravir/lamivudine? ▼
Reading a wide Integrase Inhibitor / NRTI Combination peer set (1 records)
dolutegravir/lamivudine (Dovato) sits in a wide Integrase Inhibitor / NRTI Combination peer set (1 of 1 class peers shown). Labeled indication field for dolutegravir/lamivudine: Dovato is used to treat HIV-1 infection in adults and adolescents (12 years and older, weighing at least 55 pounds).
Top FAERS reaction fields for dolutegravir/lamivudine total 7,993 reports across 10 reactions, set beside bictegravir/emtricitabine/tenofovir. Counts are exposure-weighted submissions, not per-patient risk.
Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for dolutegravir/lamivudine: see also the generic vs brand label guide when reading Dovato SPL strings.
Read our methodology - how this data is sourced, computed, and verified.